Sino-US biotechnology company AbelZeta Pharma Inc., operating in Rockville, Maryland, and Shanghai, China, has received implicit approval for its autologous armored GPC3-targeted chimeric antigen receptor (CAR) T cell therapy, C-CAR031, developed by its subsidiary, Shanghai Cellular Biopharmaceutical Group Ltd. The therapy is intended for the treatment of GPC3+ advanced or recurrent hepatocellular carcinoma (HCC).
In December 2023, AbelZeta entered into a partnership with UK pharmaceutical giant AstraZeneca for the co-development of C-CAR031. The therapy leverages an innovative GPC3-targeted CAR-T design by AstraZeneca, utilizing their transforming growth factor-beta receptor II (TGFβRII) dominant negative armoring discovery platform. AbelZeta is responsible for the manufacturing of the molecule in China. AstraZeneca has committed to paying AbelZeta upfront and milestone payments for the co-development and commercialization of C-CAR031 in China, as well as royalties from the global development of AZD58581, a related therapy. AstraZeneca retains sole responsibility for AZD58581 outside of China.- Flcube.com
